would have the option of chemotherapy rather than transplantation with the same overall long-term outcome. This is an important decision, as transplantation is associated with a 20% mortality risk and increased morbidity.
Moving knowledge to the clinic
While knowledge banks containing large numbers of patients will be important, the numbers required to address current key clinical questions are not staggeringly large. The study by Gerstung et al. reports on 1,540 patients, with the dramatic finding that almost one-quarter of patients can have their therapy decision changed on the basis of this knowledge bank approach. Of course, as patients are divided into smaller and smaller clinically relevant subgroups, the numbers will need to increase. However, the ability to dramatically inform treatment decisions as the authors demonstrate, with considerable benefits in regard to morbidity and mortality and substantial potential cost savings, epitomizes the goals of precision oncology.
Some may reasonably argue that a knowledge bank approach has always been used in clinical medicine. That knowledge bank resides within experienced clinicians who take information from various sources, most of which imperfectly reflect the clinical scenario of the patient in front of them, and synthesize the information to make a treatment decision. This 'clinical judgment' is based on an individual clinician's experience and knowledge base, which the 'knowledge banks' of the future aim to emulate and enhance.
As demonstrated by Gerstung et al., we can refine current therapeutic choices for available therapies using a knowledge bank approach. This then raises the question of whether the data reported here are ready to be used in the clinic as part of routine practice. In the current environment, the answer is 'no' , health system, where accrued data inform ongoing development of interventions and processes. Many large-scale efforts have been initiated on the basis of this concept, including the 100,000 Genomes Project in the UK 2 , the Precision Medicine Initiative in the United States 3 and the Global Alliance for Genomics and Health 4 , as well as many others across the globe.
The central belief is that having these data together will allow clinicians to make betterinformed choices with regard to individual patients. However, the mechanism for making these treatment decisions in a robust way and the metrics, parameters and statistics that will be required are yet to be established. The article by Gerstung et al. 1 is perhaps the first description of how a knowledge bank approach can, and potentially should, be used to inform clinical decisions. In this case, the article explores the knowledge bank idea in the context of AML. Treatment of this disease has advanced dramatically over the last several decades, and central to treatment is the requirement for a bone marrow transplant. Although effective, bone marrow transplantation is not without significant morbidity and potential mortality, and it has a substantial cost implication.
The authors show that, by compiling the genetic, clinical and molecular attributes for individual patients, they can cluster the patients into subgroups where more informed decisions can be made about an individual's treatment choice (Fig. 1) . Perhaps the most challenging question concerning transplantation in AML is whether or not to transplant at first remission after induction chemotherapy. Patients who are in remission can receive either consolidation chemotherapy or a bone marrow transplant. There are currently no means to determine which path is optimal for each patient. Using the knowledge bank as presented by Gerstung et al., 20-25% of patients Our understanding of the molecular diversity of disease is increasing dramatically, with the unveiling of vast complexity. The longstanding premise that diseases that appear morphologically similar or even identical are underpinned by similar molecular and genetic abnormalities has proven to be incorrect. As a consequence, developing therapies that target specific molecular processes for these diseases is becoming more and more challenging, as ever-increasing subgroups of diminishing size are replacing what was previously a single disease entity. This perhaps explains why many potential therapies have failed, particularly in cancer, and why many current therapies are only effective in subgroups that cannot be predicted before treatment. Given these challenges, how do we approach the treatment of disease with what is now variably termed precision, personalized, individualized or stratified medicine? On page 332 of this issue, Peter Campbell, Hartmut Döhner and colleagues present one potential approach for making individualized clinical care decisions in the treatment of patients with acute myeloid leukemia (AML) 1 . The approach leverages information from a large number of participants with AML to predict the best treatment for an individual patient.
The knowledge bank approach
At first observation, this approach may seem obvious: accumulate a knowledge base-often referred to as a knowledge bank-that captures the clinical features and molecular pathology of diseases for many patients, ideally within a health system environment, to guide optimal treatment choices. The end goal of such a strategy is to enable what is referred to as a self-learning
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The ultimate goal of precision medicine is to use population-based molecular, clinical and other data to make individually tailored clinical decisions for patients, although the path to achieving this goal is not entirely clear. a new study shows how knowledge banks of patient data can be used to make individual treatment decisions in acute myeloid leukemia.
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Cancer Research Centre, University of Glasgow, Glasgow, UK. e-mail: andrew.biankin@glasgow.ac.uk not be tractable to test using traditional clinical trial designs. Defining quality standards, particularly for clinical data and metrics, around what is considered to be an effective intervention and the path to broader implementation and regulatory approval will be vital if we are to effectively realize the promise of knowledge banks for clinical medicine. and a randomized, appropriately controlled study is feasible to address this question and further validate the selection model before implementation. Yet, if the ultimate goal is to use knowledge banks to improve healthcare and we are faced with an ever-increasing diversity and complexity of disease, data emerging from larger knowledge banks may Figure 1 The knowledge bank approach. A knowledge bank accrues information on parameters that are relevant to the disease and its treatment, permitting novel, generalizable insights about the disease and its subgroups. An individual patient's specific characteristics are reflected upon the knowledge bank to define the individual's risk profile for different treatment choices. As the number of participants in the knowledge bank grows, the confidence in predictions for individual patients continuously grows. The sediment plots show the risk of each outcome over time for each treatment choice. HSCT, hematopoietic stem cell transplantation; CR1, first complete remission. Time from CR1 (years) Time from CR1 (years) Convergence and divergence in sex-chromosome evolution Catherine L Peichel a sequence assembly of the chicken w chromosome enables reconstruction of the gene content of the w chromosome across 14 bird species and shows striking similarities in the maintenance of broadly expressed and dosage-sensitive genes on highly degenerate sex chromosomes in both birds and mammals. However, the chicken w chromosome is not enriched for genes with expression in female-specific tissues, providing an intriguing contrast to the acquisition and amplification of genes with testis-specific expression on mammalian Y chromosomes and suggesting that the inheritance of chromosomes solely through females or males can lead to different evolutionary outcomes.
